Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.56 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DDO | Q99489 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31450343 | 0.90 | HCAR2 (0.63) | HCAR2HCAR1MKNK1MKNK2KDM4E | |
| SCHEMBL31418211 | 0.83 | KDM4E (0.50) | HCAR1KDM4EALDH1A1POLBLMNA | |
| SCHEMBL3181717 | 0.80 | MKNK1 (0.69) | HCAR2MKNK1MKNK2KDM4EALDH1A1 | |
| SCHEMBL28498113 | 0.80 | HCAR2 (0.63) | HCAR2HCAR1MKNK1MKNK2KDM4E | |
| SCHEMBL31418298 | 0.79 | CYP2C9 (0.54) | ALDH1A1POLBCA12CA1CA2 | |
| SCHEMBL28134052 | 0.79 | MKNK1 (0.62) | HCAR2MKNK1MKNK2KDM4EALDH1A1 | |
| SCHEMBL2900222 | 0.78 | MKNK1 (0.68) | HCAR2MKNK1MKNK2KDM4EALDH1A1 | |
| SCHEMBL31475536 | 0.77 | HCAR2 (0.56) | HCAR2MKNK1MKNK2AURKA | |
| SCHEMBL25544943 | 0.77 | HCAR2 (0.56) | HCAR2MKNK1MKNK2AURKA | |
| SCHEMBL15265103 | 0.75 | CHEK1 (0.64) | MKNK1MKNK2CHEK1EGFRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| WO-2025015420-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | FAAH, FAAH2, MGLL | HCAR2 64/4885HCAR1 182/4885MKNK1 3680/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | HCAR2 64/4885HCAR1 182/4885MKNK1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.